Presentation on theme: "Lessons from the 4 th Century BC: “First Do No Harm” Wendy J. Wolf, MD, MPH President & CEO Maine Health Access Foundation www.mehaf.org."— Presentation transcript:
Lessons from the 4 th Century BC: “First Do No Harm” Wendy J. Wolf, MD, MPH President & CEO Maine Health Access Foundation www.mehaf.org
The Maine Health Access Foundation (MeHAF) Maine ’ s largest private non-profit health care foundation created in April 2000 from the sale of Blue Cross & Blue Shield to Anthem Charged with increasing access to care state-wide for Maine ’ s uninsured and underserved Current Assets: $110 million Annual grants & program spending: $ 5 million The MeHAF mission is to promote affordable and timely access to comprehensive quality health care, and improve the health of every Maine resident. MeHAF supports strategic solutions for Maine’s health care needs through grants and other programs, particularly for projects that serve the uninsured and medically underserved.
MeHAF has awarded millions to advance its mission and serve Maine people Since 2002, MeHAF has awarded over $30 million in cumulative grant and program support to nonprofits across Maine
MeHAF’s role in advancing access to medications for people who are uninsured, and promoting better patient and family-centered care Grant Programs: Medication Assistance Programs: Pharmacy benefit enrollment & medication management Integration Initiative: Grants to advance integrated care between primary care, mental & behavioral health, and oral health Special Grants: Medicare D outreach & enrollment with GOHPF, DHHS, Legal Services for the Elderly and Area Agencies on Aging Advocacy: ME Citizen Leadership Fund grant for Rx drug education for Maine’s seniors and people with disabilities Convening: Medication Management stakeholder group meetings Policy studies: Adverse drug event analysis Education support: Academic detailing meeting and this conference
Prescription Drugs: The good news The development of effective pharmaceuticals has revolutionized medical care, offering treatments for a vast array of acute and chronic illnesses: Some pharmaceuticals prevent or cure illnesses, especially those that historically resulted in premature death and disability (antibiotics, vaccines) Most pharmaceuticals focus on alleviating the symptoms or side effects of chronic disease The US has been a leader in the development of new pharmaceuticals and the industry is one of the nation’s most successful private sectors in the US economy.
Prescription Drugs: The not-so-good news The growth of prescription drugs has resulted in an explosion of polypharmacy that often causes negative health outcomes The rise of prescription drug costs is a significant factor in the rise of overall health care costs in Maine and the USA, and the retail prices of Rx drugs have more than doubled over the past decade The growth of pharmaceutical industry profits has driven a greater focus on “copy-cat” drugs that target “profitable” illnesses. Direct to consumer advertising has fueled consumer demand for drug therapy for many conditions that can be improved by life-style modification
Prescription Drugs: The concerning news The growing use of pharmaceuticals in humans and animals has driven new issues for concern: Growth of pro-industry bias that has eroded the objectivity of scientists, physicians and regulators Promotion of off-label use to expand market share Rx overuse and resistance “Medicalization” of non-illness Unintended consequences of newer technologies (genetic engineering) Cross-species effects Environmental impact
Prescription Drugs: The not-so-good news Growth of Rx drug use Dangers of polypharmacy The role of medications in rising health care costs
Growth of Rx Drugs Prescription drug use is the highest ever among insured Americans* More than half of al insured Americans (51%) are taking Rx meds regularly for chronic health problems Americans buy much more medicine per person than another country Most widely used drugs: Anti-hypertensives Lipid-lowering Among seniors, 28% of women and 22% of men take > 5 meds Largest increase in 20–44 year olds primarily due to more drugs for depression, diabetes, asthma ADD, seizures *Data from Medco Health Solutions Inc, May 2008
Rise of Polypharmacy Average # of prescriptions filled by each person in the US increased from 8.9 per year in 1997 to 12.6 per year in 2007 Polypharmacy increases the risk of drug-drug interactions and adverse drug events (ADEs) ADEs account for a significant number of hospitalizations in Maine (based on primary or secondary discharge diagnosis) Quality medication management needs to focus on managing ALL medications – and DISCONTINUING medications that are ineffective or no longer needed
Prescription drugs account for a significant proportion of National Health Expenditures Levit et al. Health Affairs, Jan/Feb 2003 and 2005 CMS Services Data
Projected increases in national health expenditures for prescription drugs (in billions) DHHS/CMS projections
Why are prescription drugs so costly? Drug research & development is costly PhRMA estimates the average cost of bringing one new drug to the market is $500 million The industry estimates this process takes an average of 12-15 years However, the largest portion of the pharmaceutical industry’s budget goes toward advertising and marketing rather than research and development Pharmaceutical companies spend 2 ½ times more on marketing and administration than on research and development. Academic researchers in public and private institutions frequently spearhead the development of new drugs with funding from the federal National Institutes of Health. Although tax dollars support this research, these discoveries are increasingly sold to private industry for development and profit.
Direct to consumer advertising is a significant factor driving up the cost of Rx drugs – but does it result in better quality and health outcomes? The drug industry spends $3 billion/year in DTC ads The industry argues: Educates patients about medical conditions, treatment options, side effects, etc Prompts dialogue between providers and patients Improves appropriateness of prescribing Improves compliance Others say: Increases cost by prompting requests for brand name drugs Promotes newer more expensive Rx, often with higher profit margin
Prescription Drugs: Opportunities for advocacy The growing use of pharmaceuticals in humans and animals has prompted new issues for advocacy: Growth of pro-industry bias that has eroded the objectivity and trust by scientists, physicians and regulators Promotion of off label use to expand market share “Medicalization” of non-illness Rx overuse and resistance Unintended consequences of newer technologies (genetic engineering) Cross-species effects Environmental impact
Prescription Drugs: Pro-Industry Bias Erosion of Firewalls between Science and Industry The pharmaceutical industry has transformed the culture of medical school and scientists conducting basic research, instilling a pro-industry bias* Example: Dr. Charles Nemeroff of Emory University—the principal investigator on a government-financed study of antidepressant drugs made by GlaxoSmithKline—failed to report almost a half a million dollars he was paid in fees and expenses from the drug company while he led the study (NY Times, 10/11/2008) Researchers were 5 times more likely to recommend a drug when a study was funded by the industry rather than by a non-profit Drug companies pay for postgraduate accreditation courses for doctors. Under the guise of offering educational opportunities for doctors, drug companies use the lectures and conferences they sponsor to push their products Schools and medical centers often hold equity in the start-up companies that sponsor their research *Angell, JAMA Sept 2008
Prescription Drugs: Opportunities for advocacy Special issues for children Promotion of off label use Applying adult models to childhood conditions “Medicalization” of non-illness Rx overuse and resistance Unintended consequences
Prescription Drugs: Opportunities for advocacy Insure access – and advocate for standardization of pharmacy benefit programs Promote quality medication management that insure that unneeded or ineffective medications are eliminated (and returned to drug disposal sites). Advocate for comprehensive health information through better health IT and HealthInfoNet Support policies that insure scientific rigor, strict attention to conflict of interest and insure firewalls between industry, scientists, and providers to insure science and evidence is unbiased (Ex: Grassley/Kohl bill that would require drug companies to publicly disclose payments to physicians > $500/yr) Broad program to support academic detailing to combat promotion of brand name drugs and off label use Advance public policies that balance medication costs with quality and effectiveness Consider regulation to limit “medicalization” of non-illness so insurers are protected from mandates to cover non-evidence based treatments Proactive hospital and insurer policies, and consumer education to prevent Rx overuse and resistance Surveillance/examination of unintended consequences of newer technologies (genetic engineering) Convening of key leaders/researchers to examine cross-species effects Policies and public education to mitigate environmental impact
These issues touch every person in Maine – and we all have a stake in addressing these health care challenges